Joshua Phillips Sells 12,710 Shares of Sera Prognostics, Inc. (NASDAQ:SERA) Stock

Sera Prognostics, Inc. (NASDAQ:SERA) Director Joshua Phillips sold 12,710 shares of the business’s stock in a transaction on Friday, January 10th. The shares were sold at an average price of $7.40, for a total transaction of $94,054.00. Following the completion of the sale, the director now directly owns 5 shares of the company’s stock, valued at approximately $37. This trade represents a 99.96 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.

Joshua Phillips also recently made the following trade(s):

• On Monday, January 13th, Joshua Phillips sold 12,163 shares of Sera Prognostics stock. The stock was sold at an average price of $6.39, for a total value of $77,721.57.

Sera Prognostics Stock Performance

NASDAQ:SERA opened at $6.60 on Friday. Sera Prognostics, Inc. has a 52-week low of $4.98 and a 52-week high of $12.35. The stock’s 50 day moving average price is $7.40 and its 200 day moving average price is $7.31.

Sera Prognostics (NASDAQ:SERA) last announced its earnings results on Wednesday, November 6th. The company reported ($0.24) EPS for the quarter, missing analysts’ consensus estimates of ($0.22) by ($0.02). The firm had revenue of $0.03 million for the quarter, compared to analyst estimates of $0.09 million. During the same quarter last year, the firm earned ($0.23) earnings per share. As a group, equities research analysts predict that Sera Prognostics, Inc. will post -0.96 EPS for the current year.

Institutional Investors Weigh In On Sera Prognostics

Hedge funds have recently made changes to their positions in the business. Quest Partners LLC increased its position in Sera Prognostics by 533.5% in the 3rd quarter. Quest Partners LLC now owns 6,430 shares of the company’s stock valued at $50,000 after acquiring an additional 5,415 shares during the period. The Manufacturers Life Insurance Company acquired a new position in shares of Sera Prognostics in the second quarter valued at approximately $68,000. SG Americas Securities LLC purchased a new stake in shares of Sera Prognostics during the third quarter worth approximately $78,000. Prime Capital Investment Advisors LLC purchased a new position in Sera Prognostics in the 3rd quarter valued at $104,000. Finally, Jane Street Group LLC increased its stake in Sera Prognostics by 24.8% in the 3rd quarter. Jane Street Group LLC now owns 14,225 shares of the company’s stock valued at $111,000 after buying an additional 2,826 shares during the period. Institutional investors and hedge funds own 54.64% of the company’s stock.

About Sera Prognostics

Sera Prognostics, Inc, a women's health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes in the United States. The company develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in singleton pregnancies.